BioSig (BSGM) 10-Q 28 Jul 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 28, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'BIOSIG TECHNOLOGIES, INC.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	9,821,288
Amendment Flag	'false	'
Entity Central Index Key	'0001530766	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$42,188	$302,187
Prepaid expenses	21,806	0
Total current assets	63,994	302,187
Property and equipment, net	16,297	24,866
Other assets:	'	'
Deposits	25,000	25,000
Total assets	105,291	352,053
Current liabilities:	'	'
Accounts payable and accrued expenses, including $111,208 and $92,308 to related parties as of June 30, 2014 and December 31, 2013, respectively	552,087	819,330
Advances, related party	500	30,781
Liability to placement agent	0	52,800
Dividends payable	330,857	414,967
Total current liabilities	883,444	3,017,501
Series C 9% Convertible Preferred stock, liquidation preference of $2,781,000, net of debt discount of $14,754 and $483,893, respectively	2,766,246	2,297,107
Stockholders' deficit	'	'
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock	'	'
Common stock, $0.001 par value, authorized 50,000,000 shares, 9,821,288 and 8,412,101 issued and outstanding as of June 30, 2014 and December 31, 2013, respectively	9,821	8,412
Additional paid in capital	12,524,784	9,036,038
Accumulated deficit	-16,079,004	-14,007,005
Total stockholders' deficit	-3,544,399	-4,962,555
Total liabilities and stockholders' deficit	105,291	352,053
Series A Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable Preferred Stock	0	884,601
Series B Preferred Stock [Member]	'	'
Current liabilities:	'	'
Redeemable Preferred Stock	$0	$815,022

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
Accounts payable and accrued expenses, related parties (in Dollars)	$111,208	$92,308	'	'
Preferred stock, liquidation preference (in Dollars)	'	'	922,000	887,500
Preferred stock, debt discount (in Dollars)	'	'	$37,399	$72,478
Preferred stock, par value (in Dollars per share)	$0.00	$0.00	'	'
Preferred stock, shares authorized	1,000,000	1,000,000	200	600
Common stock, par value (in Dollars per share)	$0.00	$0.00	'	'
Common stock, shares authorized	50,000,000	50,000,000	'	'
Common stock, shares issued	9,821,288	8,412,101	'	'
Common stock, shares outstanding	9,821,288	8,412,101	'	'

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Operating expenses:	'	'	'	'
Research and development	$99,893	$178,507	$222,044	$484,846
General and administrative	484,502	1,041,972	1,086,067	4,061,431
Depreciation	4,134	4,259	8,569	7,951
Total operating expenses	588,529	1,224,738	1,316,680	4,554,228
Loss from operations	-588,529	-1,224,738	-1,316,680	-4,554,228
Other income (expense):	'	'	'	'
Interest income (expense)	-7,958	-114	-9,056	-20,535
Financing costs	-190,731	-614,566	-579,016	-975,066
Loss before income taxes	-787,218	-1,839,418	-1,904,752	-5,549,829
Income taxes (benefit)	0	0	0	0
Net loss	-787,218	-1,839,418	-1,904,752	-5,549,829
Preferred stock dividend	-83,223	-75,243	-167,247	-126,760
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	($870,441)	($1,914,661)	($2,071,999)	($5,676,589)
Net loss per common share, basic and diluted (in Dollars per share)	($0.10)	($0.23)	($0.24)	($0.69)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	8,782,383	8,185,589	8,633,374	8,180,434

STATEMENT_OF_STOCKHOLDERS_DEFI

STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]	Total
	Common Stock [Member]	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]
Balance, December 31, 2013 at Dec. 31, 2013	'	'	'	'	'	'	$8,412	$9,036,038	($14,007,005)	($4,962,555)
Balance, December 31, 2013 (in Shares) at Dec. 31, 2013	'	'	'	'	'	'	8,412,101	'	'	8,412,101
Sale of common stock	'	'	'	'	'	'	337	732,329	'	732,666
Sale of common stock (in Shares)	'	'	'	'	'	'	337,468	'	'	'
Common stock issued upon conversion of preferred stock and accrued dividends	578	1,062,753	1,063,331	494	997,032	997,526	'	'	'	'
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)	577,901	'	'	493,818	'	'	'	'	'	'
Donated capital	'	'	'	'	'	'	'	87,500	'	87,500
Equity warrants issued to placement agent for sale of common stock	'	'	'	'	'	'	'	52,800	'	52,800
Fair value of vested options	'	'	'	'	'	'	'	556,332	'	556,332
Preferred stock dividend	'	'	'	'	'	'	'	'	-167,247	-167,247
Net loss	'	'	'	'	'	'	'	'	-1,904,752	-1,904,752
Balance, June 30, 2014 at Jun. 30, 2014	'	'	'	'	'	'	$9,821	$12,524,784	($16,079,004)	($3,544,399)
Balance, June 30, 2014 (in Shares) at Jun. 30, 2014	'	'	'	'	'	'	9,821,288	'	'	9,821,288

STATEMENT_OF_STOCKHOLDERS_DEFI1

STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) (Common Stock [Member], USD $)	Jun. 30, 2014	Jun. 30, 2014
	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
Common stock issued, per share	$1.84	$2.02

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($1,904,752)	($5,549,829)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Depreciation	8,569	7,951
Amortization of debt discount	579,016	995,066
Stock based compensation	556,332	2,716,746
Fair value of warrants issued for services	0	837,243
Changes in operating assets and liabilities:	'	'
Prepaid expenses	-21,806	0
Accounts payable	-178,737	-154,241
Deferred rent payable	-1,006	0
Net cash used in operating activities	-962,384	-1,147,064
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchase of property and equipment	0	-9,765
Net cash used in investing activity	0	-9,765
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Net proceeds from the sale of Series C preferred stock and warrants	0	1,484,070
Proceeds from sale of common stock	732,666	0
Payments of related party notes	0	-30,000
Net repayments of related party advances	-30,281	-16,540
Net cash provided by financing activities	702,385	1,437,530
Net (decrease) increase in cash and cash equivalents	-259,999	280,701
Cash and cash equivalents, beginning of the period	302,187	24,237
Cash and cash equivalents, end of the period	42,188	304,938
Supplemental disclosures of cash flow information:	'	'
Cash paid during the period for interest	0	0
Cash paid during the period for income taxes	0	0
Non cash investing and financing activities:	'	'
Convertible bridge notes payable exchanged for preferred shares	0	600,000
Series A Preferred Stock [Member]	'	'
Non cash investing and financing activities:	'	'
Common stock issued upon conversion preferred stock and accrued dividends	1,063,331	0
Series B Preferred Stock [Member]	'	'
Non cash investing and financing activities:	'	'
Common stock issued upon conversion preferred stock and accrued dividends	$997,526	$0

NOTE_1_SUMMARY_OF_SIGNIFICANT_

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.
	Business and organization
	BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
	Interim Financial Statements
	The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
	The condensed balance sheet as of December 31, 2013 has been derived from audited financial statements.
	Operating results for the six months ended June 30, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2013 filed with the Company’s Form S-1/A with the Securities and Exchange Commission on June 20, 2014 .
	Basis of presentation
	The Company's primary efforts are devoted to conducting research and development principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. In addition, the Company has stockholders' deficiencies at June 30, 2014 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.
	The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.
	Use of estimates
	The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. Significant estimates include the useful life of fixed assets and assumptions used in the fair value of stock-based compensation.
	Fair Value of Financial Instruments
	The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.
	Research and development costs
	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $99,893  and $222,044 for the three and six months ended June 30, 2014, respectively; and $178,507 and $484,846 for the three and six months ended June 30, 2013, respectively.
	Income Taxes
	The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
	Net Income (loss) Per Common Share
	The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
	The computation of basic and diluted loss per share as of June 30, 2014 and 2013 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.
	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		June 30,		June 30,
		2014		2013
	Series A convertible preferred stock		-		501,089
	Series B convertible preferred stock		-		451,726
	Series C convertible preferred stock		1,854,019		1,158,851
	Options to purchase common stock		2,990,977		2,990,977
	Warrants to purchase common stock		4,502,459		1,608,003
	Totals		9,347,455		6,710,646
	Stock Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
	As of June 30, 2014, the Company had 2,990,977 options outstanding to purchase shares of common stock, of which 1,904,659 were vested.
	Registration Rights
	The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists,  to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense for the liability under the registration rights agreements.
	Recent Accounting Pronouncements
	The Company has adopted Accounting Standards Update (ASU) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification™.
	A development stage entity is one that devotes substantially all of its efforts to establishing a new business and for which: (a) planned principal operations have not commenced; or (b) planned principal operations have commenced, but have produced no significant revenue. For example, many start-ups or even long-lived organizations that have not yet begun their principal operations or do not have significant revenue would be identified as development stage entities.
	For public business entities, the presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted.
	The Company has chosen to adopt the provisions of the ASU, hence all of the past development stage disclosures and presentations have been eliminated.
	There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

NOTE_2_PROPERTY_AND_EQUIPMENT

NOTE 2 - PROPERTY AND EQUIPMENT	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 2 – PROPERTY AND EQUIPMENT
	Property and equipment as of June 30, 2014 and December 31, 2013 is summarized as follows:
		June 30,			December 31,
		2014			2013
	Computer equipment	$	50,937		$	50,937
	Furniture and fixtures		7,803			7,803
	Subtotal		58,740			58,740
	Less accumulated depreciation		(42,443	)		(33,874	)
	Property and equipment, net	$	16,297		$	24,866
	Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
	Depreciation expense was $4,134 and $8,569 for the three and six months ended June 30, 2014, respectively; and $4,259 and $7,951 for the three and six months ended June 30, 2013, respectively .

NOTE_3_ACCOUNTS_PAYABLE_AND_AC

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses at June 30, 2014 and December 31, 2013 consist of the following:
		June 30,		December 31,
		2014		2013
	Accrued accounting and legal	$	194,271	$	300,893
	Accrued reimbursements		9,898		17,797
	Accrued consulting		102,337		214,481
	Accrued research and development expenses		30,639		64,670
	Accrued credit card obligations		18,243		20,425
	Accrued payroll		-		35,896
	Accrued liquidated damages		55,620		48,668
	Accrued office and other		41,079		16,500
	Accrued settlement related to arbitration		100,000		100,000
		$	552,087	$	819,330

NOTE_4_REDEEMABLE_PREFERRED_ST

NOTE 4 - REDEEMABLE PREFERRED STOCK	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Preferred Stock [Text Block]	'
	NOTE 4 — REDEEMABLE PREFERRED STOCK
	Series A Preferred Stock
	In May 2011, the Board of Directors authorized the issuance of up to 200 shares of Series A Preferred Stock (the “Series A preferred stock”).
	The Series A preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $5,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 5% per annum of the Stated Value of $5,000 per share, payable quarterly beginning on August 31, 2011 and are cumulative.  The holders of Series A preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series A preferred stock, the Company cannot, (a) alter or change adversely the powers, preferences or rights given to the Series A preferred stock or alter or amend the Certificate of Designation.
	The Series A preferred stock is mandatorily redeemable on December 31, 2014 (as modified) at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends.  If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.
	The Series A preferred stock is convertible (as amended), automatically, inclusive of any accrued and unpaid dividends, immediately into the Company’s common stock upon the Company becoming subject to the reporting requirements under Section 13 or 15(d) of the Securities and Exchange Act of 1934, as amended at conversion price of $1.84 per share.
	On February 6, 2013, in connection with the amendment to the Series A preferred stock defining the conversion feature, the Company reclassified the associated financing costs as a debt discount against the carrying value of the preferred stock.
	As of December 31, 2013, 184.4 shares of Series A preferred stock were issued and outstanding with accrued dividends of $119,355 payable on the Series A preferred stock.
	On June 23, 2014, upon the effectiveness of the Company’s registration statement, the Company issued an aggregate of 577,901 shares of its common stock in exchange for all the outstanding Series A preferred stock and accrued dividends of $141,331.
	Series B Preferred Stock
	On November 28, 2011, the Board of Directors authorized the issuance of up to 600 shares of Series B Preferred Stock (the “Series B preferred stock”).
	The Series B preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $5,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 5% per annum of the Stated Value of $5,000 per share, payable quarterly beginning on December 31, 2011 and are cumulative.  The holders of Series B preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series B preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series A preferred stock or alter or amend the Certificate of Designation.
	The Series B preferred stock is mandatorily redeemable on December 31, 2014 at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends.  If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.
	The Series B preferred stock is convertible (as amended), automatically, inclusive of any accrued and unpaid dividends, immediately into the Company’s common stock upon the Company becoming subject to the reporting requirements under Section 13 or 15(d) of the Securities and Exchange Act of 1934, as amended at conversion price of $2.02 per share.
	On February 6, 2013, in connection with the amendment to the Series B preferred stock defining the conversion feature, the Company reclassified the associated financing costs as a debt discount against the carrying value of the preferred stock.
	As of December 31, 2013, 177.5 shares of Series B preferred stock were issued and outstanding. With accrued dividends of $88,872 payable on the Series B preferred stock.
	On June 23, 2014, upon the effectiveness of the Company’s registration statement, the Company issued an aggregate of 493,818 shares of its common stock in exchange for all the outstanding Series B preferred stock and accrued dividends of $110,026.

NOTE_5_SERIES_C_9_CONVERTIBLE_

NOTE 5 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	6 Months Ended
	Jun. 30, 2014
Convertible Preferred Stock [Abstract]	'
Convertible Preferred Stock [Text Block]	'
	NOTE 5 — SERIES C 9% CONVERTIBLE PREFERRED STOCK
	On January 9,  2013, the Board of Directors authorized the issuance of up to 4,200 shares of Series C Convertible Preferred Stock (the “Series C Convertible Preferred Stock”).
	The Series C convertible preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends ; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the Stated Value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of Series C preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the Certificate of Designation.
	Each share of Series C preferred stock is convertible, at the holder’s option, inclusive of any accrued and unpaid dividends, at conversion price of $1.50 (as reset).
	If, at any time while the Series C preferred stock is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then conversion price (“Base Conversion Price”), then the conversion price shall be reduced to equal the Base Conversion Price.  Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  During the six months ended June 30, 2014, the resets provisions as described above resulted in the conversion price reset to $1.50.
	The Series C preferred stock contains triggering events which would require redemption at (i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%.   The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C preferred stock outside of equity.
	In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrant provides if, at any time while the warrant is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any person to acquire shares of common stock at an effective price per share that is lower than the then conversion price (“base conversion price”), then the conversion price shall be reduced to equal the Base Conversion Price.
	Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  In addition, the warrants provides for at any time after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no current prospectus available for the resale of the warrant shares by the holder, then  the warrant may only be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of Warrant Shares equal to defined formula. During the six months ended June 30, 2014, the resets provisions as described above resulted in an additional 984,674 warrants issued with an exercise price reset to $1.50 all Series C warrants..
	In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the Series C preferred stock when it was issued. The Company allocated the net proceeds between the  intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.  The aggregate debt discount, comprised of the relative intrinsic value the conversion option ($1,303,671),  relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590); total of $2,781,000, is amortized over one year as interest expense, the date a possible redemption feature, outside of the Company’s control, would be available to the Series C stockholders
	The Company valued the warrants in accordance with ASC 470-20 using the Black-Scholes pricing model and the following assumptions: contractual terms of 5 years, an average risk free interest rate of 0.39% to 1.40%, a dividend yield of 0%, and volatility of 123.41% to 125.33%.
	During the month of February 2013, the holders of the Convertible Bridge Notes (See Note 7) converted into 600 shares of the Company’s Series C 9% Convertible Preferred Stock.
	During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C 9% Convertible Preferred Stock for net proceeds of $1,814,910.
	The Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  There is no established market for the Company’s common stock.
	Series C preferred stock issued and outstanding totaled 2,781 as of June 30, 2014 and December 31, 2013.  As of June 30, 2014 and December 31, 2013, the Company has accrued $330,856 and $206,740 dividends payable on the Series C preferred stock.
	Registration Rights Agreement
	The Company entered into a Registration Rights Agreement  in connection with the sale and issuance of the Series C preferred stock.  The Company is required to file a registration statement registering for resale the  (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution,  recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.
	The Company is required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold.  If the Company fails to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.
	On July 22, 2013, the Company met its required filing requirement and on June 23, 2014, became effective, however did not meet the effectiveness obligation by November 22, 2013,  therefore accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement.

NOTE_6_STOCKHOLDER_EQUITY

NOTE 6 - STOCKHOLDER EQUITY	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 6 — STOCKHOLDER EQUITY
	There is not a viable market for the Company’s common stock to determine its fair value; therefore, management is required to estimate the fair value to be utilized in the determining stock based compensation costs.  In estimating the fair value, management considers recent sales of its common stock to independent qualified investors, placement agents’ assessments of the underlying common shares relating to our sale of preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair value.  Accordingly, actual results could vary significantly from management’s estimates.
	Preferred stock
	The Company is authorized to issue 1,000,000 shares of  $0.001 par value preferred stock. As of June 30, 2014 and December 31, 2013,  the Company has designated and issued 200 and 184.4 shares of Series A preferred stock, respectively, designated and issued 600 and 177.5 shares of Series B preferred stock, respectively. See Note 4.
	As of June 30, 2014 and December 31, 2013, the Company designated and  issued 4,200 and 2,781shares of Series C 9% convertible preferred stock, respectively. See Note 5.
	On June 23, 2014, the Company issued an aggregate of 577,901 and 493,818 shares of its common stock in exchange of all the issued and outstanding Series A and Series B preferred stock.
	Common stock
	The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of June 30, 2014 and December 31, 2013, the Company has 9,821,288 and 8,412,101 shares issued and outstanding, respectively.
	During the six months ended June 30, 2014, the Company entered into a securities purchase agreement with investors pursuant to which the Company issued 337,468 shares of common stock and five-year warrants for aggregate proceeds of $732,666.

NOTE_7_OPTIONS_AND_WARRANTS

NOTE 7 - OPTIONS AND WARRANTS	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Shareholders' Equity and Share-based Payments [Text Block]	'
	NOTE 7 — OPTIONS AND WARRANTS
	There is not a viable market for the Company’s common stock to determine its fair value, therefore management is required to estimate the fair value to be utilized in the determining stock based compensation costs.  In estimating the fair value, management considers recent sales of its common stock to independent qualified investors, placement agents’ assessments of the underlying common shares relating to our sale of preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair value.  Accordingly, actual results could vary significantly from management’s estimates
	On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “2012 Plan) and terminated the Long-Term Incentive Plan (the “ 2011 Plan”). The Plan provides for the issuance of options to purchase up to 3,500,000 shares of the Company’s common stock to officers, directors, employees and consultants of the Company. Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on quoted market price or in absence of such quoted market price, by the Board of Directors in good faith.
	Additionally, the vesting period of the grants under the Plan will be determined by the Committee, in its sole discretion, and expiration period not more than ten years. The Company reserved 500,000 shares of its common stock for future issuance under the terms of the Plan.
	As of June 30, 2014, the Company granted an aggregate of 2,990,977 options to directors and key consultants with an aggregate estimated fair value of $3,380,851.
	A summary of the stock option activity and related information for the 2012 Plan for the six months ended June 30, 2014 is as follows:
			Shares		Weighted-Average			Weighted-Average	Aggregate Intrinsic
					Exercise Price			Remaining	Value
								Contractual Term
	Outstanding at January 1, 2014		2,990,977		$	2.05		6.02	$	-
	Grants		-		$	-		-	$	-
	Exercised		-
	Forfeitures or expirations		-
	Outstanding at June 30,		2,990,977		$	2.05		5.52	$	1,343,204
	2014
	Vested and expected to vest at		2,990,977		$	2.05		5.52	$	1,343,204
	30-Jun-14
	Exercisable at June 30,		1,904,659		$	2.08		5.74	$	805,734
	2014
	The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated stock price of $2.50 as of June 30, 2014, which would have been received by the option holders had those option holders exercised their options as of that date.
	The fair value of all options vesting during the three and six months ended June 30, 2014 of $212,495 and $556,332, respectively, and $643,555 and $2,658,870 for the three and six months ended June 30, 2013, respectively, was charged to current period operations.  Unrecognized compensation expense of $544,106 at June 30, 2014 will be expensed in future periods.
	Warrants
	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at June 30, 2014:
	Exercise			Number		Expiration
	Price			Outstanding		Date
	$	0.001		383,320				Jan-20
	$	1.5		3,721,518		Feb-18	to	September 2018
	$	1.84		35,076				Jan-20
	$	2.02		30,755				Jan-20
	$	3.67		193,934		Dec-18	to	January 2019
	$	3.75		137,856				Apr-19
				4,502,459
	In February 2014, as described in the terms of the warrants issued in connection with the sale of the Series C preferred stock, the Company reset 2,138,800 previously issued warrants from a exercise price of $2.61 per share to $1.50.  In addition, the Company was required to increase the number of issued warrants to an aggregate total of  3,721,518 warrants.
	On January 31, 2014, the Company issued an aggregate of 64,626 warrants to purchase the Company’s common stock at $3.67 per share for five years in connection with the sale of the Company’s common stock.
	In April 2014, the Company issued an aggregate of 137,856 warrants to purchase the Company’s common stock at $3.75 per share for five years in connection with the sale of the Company’s common stock.

NOTE_8_RELATED_PARTY_TRANSACTI

NOTE 8 - RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 8 – RELATED PARTY TRANSACTIONS
	The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception in February 2009.  No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. The net amount outstanding at June 30, 2014 and December 31, 2013  was $500 and $30,781, respectively.
	During the six months ended June 30, 2014, one of the Company’s board of directors forgave an outstanding obligation of $87,500 for services.  Accordingly, the Company reclassified the liability to equity as donated capital.

NOTE_9_COMMITMENTS_AND_CONTING

NOTE 9 - COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 9 - COMMITMENTS AND CONTINGENCIES
	Operating leases
	On May 31, 2014, the Company extended its expiring three-year lease for office space in Los Angeles, California for one additional year, with monthly payments of $6,530 beginning September 1, 2014.
	Litigation
	On January 7, 2014, David Drachman, the Company’s former chief executive officer and president, filed a statement of claim against the Company with the American Arbitration Association with respect to his resignation from his positions with us in November 2013.  Mr. Drachman alleges, among other things, that (i) the Company misled him with respect to the status of our technology and required him to perform capital raising duties that had not been previously agreed upon, (ii) he resigned from his positions with us for good reason, as such term was defined in his employment agreement with the Company, and (iii) he, in his individual capacity, has full rights to the ownership and control of a patent application describing a combined ablation and recording unit directed at the use of electrocardiography sensing for control of radiofrequency renal denervation that we filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with the Company.
	Mr. Drachman is seeking, among other things, (a) payment of his salary and pro-rated bonus for the time he served in his positions with the Company and the severance payments due under his employment agreement, which include 12 months of base salary and full bonus payments, with the total sum of payments equaling approximately $612,000, including $58,000 of accrued and unpaid salary, (b) full vesting of stock options equivalent to 10% of our outstanding common stock, and (c) a declaration by us that Mr. Drachman has full rights to the ownership and control of the patent application related to a combined ablation and recording unit that the Company filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with the Company.
	We intend to fully dispute Mr. Drachman’s allegations and his relief sought to the fullest extent permitted by the law and believe them to be wholly without merit.  On February 21, 2014, we filed an answer to Mr. Drachman’s statement of claim that disputed all of Mr. Drachman’s claims against us and counter-claimed against Mr. Drachman, seeking declaratory judgment concerning our rights to the ownership and control of the patent application related to a combined ablation and recording unit that we filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with us.  A hearing date for the arbitration has been set for September 2014.  We believe that the intellectual property included in the patent application does not represent our core proprietary intellectual property but instead represents a different use and application of our proprietary technology.

NOTE_10_FAIR_VALUE_OF_FINANCIA

NOTE 10 - FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	NOTE 10 - FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company follows the provisions of ASC 825-10.  For financial assets and liabilities included within the scope of ASC 825-10, the Company was required to adopt the provisions of ASC 825-10 prospectively as of the beginning of Fiscal 2009.  The adoption of ASC 825-10 did not have a material impact on our consolidated financial position or results of operations.
	There were no items required to be measured at fair value on a recurring basis in the financial statements as of June 30, 2014 and December 31, 2013.

NOTE_11_SUBSEQUENT_EVENTS

NOTE 11 - SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 11 – SUBSEQUENT EVENTS
	On July 14, 2014, the Company’s Board Of Directors (the “Board”) increased the size of the Board to eight members and appointed  Gregory D. Cash and Patrick J. Gallagher as members of the Board, effective as of July 15, 2014, to serve for a term expiring at the Company’s 2015 annual meeting of stockholders. In addition, the Board appointed Mr. Cash to serve as the Company’s president and chief executive officer.
	In connection with the appointment of Mr. Cash, on July 15, 2014 (the “Effective Date”), the Company entered into an employment agreement with Mr. Cash (the “Employment Agreement”). The Employment Agreement has an initial term of three years that expires on July 15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a “Qualified Financing”), Mr. Cash’s annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.
	In accordance with the Employment Agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock option to purchase 1,265,769 shares of the Company’s common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price of $2.21, which was the fair market value of the Company’s common stock on the date of grant, and a term that expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of presentation
	The Company's primary efforts are devoted to conducting research and development principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. In addition, the Company has stockholders' deficiencies at June 30, 2014 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.
	The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates
	The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. Significant estimates include the useful life of fixed assets and assumptions used in the fair value of stock-based compensation.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and development costs
	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $99,893  and $222,044 for the three and six months ended June 30, 2014, respectively; and $178,507 and $484,846 for the three and six months ended June 30, 2013, respectively.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Income (loss) Per Common Share
	The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
	The computation of basic and diluted loss per share as of June 30, 2014 and 2013 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.
	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		June 30,		June 30,
		2014		2013
	Series A convertible preferred stock		-		501,089
	Series B convertible preferred stock		-		451,726
	Series C convertible preferred stock		1,854,019		1,158,851
	Options to purchase common stock		2,990,977		2,990,977
	Warrants to purchase common stock		4,502,459		1,608,003
	Totals		9,347,455		6,710,646
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
	As of June 30, 2014, the Company had 2,990,977 options outstanding to purchase shares of common stock, of which 1,904,659 were vested.
Registration Rights Policy [Policy Text Block]	'
	Registration Rights
	The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists,  to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense for the liability under the registration rights agreements.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	The Company has adopted Accounting Standards Update (ASU) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, including the removal of Topic 915, Development Stage Entities, from the FASB Accounting Standards Codification™.
	A development stage entity is one that devotes substantially all of its efforts to establishing a new business and for which: (a) planned principal operations have not commenced; or (b) planned principal operations have commenced, but have produced no significant revenue. For example, many start-ups or even long-lived organizations that have not yet begun their principal operations or do not have significant revenue would be identified as development stage entities.
	For public business entities, the presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective one year later, in annual periods beginning after December 15, 2015. Early adoption is permitted.
	The Company has chosen to adopt the provisions of the ASU, hence all of the past development stage disclosures and presentations have been eliminated.
	There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

NOTE_1_SUMMARY_OF_SIGNIFICANT_1

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		June 30,		June 30,
		2014		2013
	Series A convertible preferred stock		-		501,089
	Series B convertible preferred stock		-		451,726
	Series C convertible preferred stock		1,854,019		1,158,851
	Options to purchase common stock		2,990,977		2,990,977
	Warrants to purchase common stock		4,502,459		1,608,003
	Totals		9,347,455		6,710,646

NOTE_2_PROPERTY_AND_EQUIPMENT_

NOTE 2 - PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'Property and equipment as of June 30, 2014 and December 31, 2013 is summarized as follows:
		June 30,			December 31,
		2014			2013
	Computer equipment	$	50,937		$	50,937
	Furniture and fixtures		7,803			7,803
	Subtotal		58,740			58,740
	Less accumulated depreciation		(42,443	)		(33,874	)
	Property and equipment, net	$	16,297		$	24,866

NOTE_3_ACCOUNTS_PAYABLE_AND_AC1

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'Accounts payable and accrued expenses at June 30, 2014 and December 31, 2013 consist of the following:
		June 30,		December 31,
		2014		2013
	Accrued accounting and legal	$	194,271	$	300,893
	Accrued reimbursements		9,898		17,797
	Accrued consulting		102,337		214,481
	Accrued research and development expenses		30,639		64,670
	Accrued credit card obligations		18,243		20,425
	Accrued payroll		-		35,896
	Accrued liquidated damages		55,620		48,668
	Accrued office and other		41,079		16,500
	Accrued settlement related to arbitration		100,000		100,000
		$	552,087	$	819,330

NOTE_7_OPTIONS_AND_WARRANTS_Ta

NOTE 7 - OPTIONS AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'A summary of the stock option activity and related information for the 2012 Plan for the six months ended June 30, 2014 is as follows:
			Shares		Weighted-Average			Weighted-Average	Aggregate Intrinsic
					Exercise Price			Remaining	Value
								Contractual Term
	Outstanding at January 1, 2014		2,990,977		$	2.05		6.02	$	-
	Grants		-		$	-		-	$	-
	Exercised		-
	Forfeitures or expirations		-
	Outstanding at June 30,		2,990,977		$	2.05		5.52	$	1,343,204
	2014
	Vested and expected to vest at		2,990,977		$	2.05		5.52	$	1,343,204
	30-Jun-14
	Exercisable at June 30,		1,904,659		$	2.08		5.74	$	805,734
	2014
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	'The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at June 30, 2014:
	Exercise			Number		Expiration
	Price			Outstanding		Date
	$	0.001		383,320				Jan-20
	$	1.5		3,721,518		Feb-18	to	September 2018
	$	1.84		35,076				Jan-20
	$	2.02		30,755				Jan-20
	$	3.67		193,934		Dec-18	to	January 2019
	$	3.75		137,856				Apr-19
				4,502,459

NOTE_1_SUMMARY_OF_SIGNIFICANT_2

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]	'	'	'	'	'	'
Research and Development Expense	$99,893	$178,507	$222,044	$484,846	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	2,990,977	'	2,990,977	'	'	2,990,977
Registration Payment Arrangement, Accrual Carrying Value	$55,620	'	$55,620	'	$48,668	'
Employee Stock Option [Member]	'	'	'	'	'	'
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	2,990,977	'	2,990,977	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares)	'	'	1,904,659	'	'	'

NOTE_1_SUMMARY_OF_SIGNIFICANT_3

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	9,347,455	6,710,646
Series A Preferred Stock [Member] | Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	0	501,089
Series B Preferred Stock [Member] | Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	0	451,726
Series C Preferred Stock [Member] | Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	1,854,019	1,158,851
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	2,990,977	2,990,977
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities	4,502,459	1,608,003

NOTE_2_PROPERTY_AND_EQUIPMENT_1

NOTE 2 - PROPERTY AND EQUIPMENT (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]	'	'	'	'
Depreciation	$4,134	$4,259	$8,569	$7,951
Minimum [Member]	'	'	'	'
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'3 years	'
Maximum [Member]	'	'	'	'
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'5 years	'

NOTE_2_PROPERTY_AND_EQUIPMENT_2

NOTE 2 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment (USD $)	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$58,740	$58,740
Less accumulated depreciation	-42,443	-33,874
Property and equipment, net	16,297	24,866
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	50,937	50,937
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$7,803	$7,803

NOTE_3_ACCOUNTS_PAYABLE_AND_AC2

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities (USD $)	Jun. 30, 2014	Dec. 31, 2013
Schedule of Accounts Payable and Accrued Liabilities [Abstract]	'	'
Accrued accounting and legal	$194,271	$300,893
Accrued reimbursements	9,898	17,797
Accrued consulting	102,337	214,481
Accrued research and development expenses	30,639	64,670
Accrued credit card obligations	18,243	20,425
Accrued payroll	0	35,896
Accrued liquidated damages	55,620	48,668
Accrued office and other	41,079	16,500
Accrued settlement related to arbitration	100,000	100,000
	$552,087	$819,330

NOTE_4_REDEEMABLE_PREFERRED_ST1

NOTE 4 - REDEEMABLE PREFERRED STOCK (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 23, 2014

31-May-11

Jun. 30, 2014

Dec. 31, 2013

Nov. 28, 2011

Dec. 31, 2013

Jun. 23, 2014

Nov. 28, 2011

Jun. 30, 2014

Dec. 31, 2013

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Other Current Liabilities [Member]

Other Current Liabilities [Member]

NOTE 4 - REDEEMABLE PREFERRED STOCK (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

1,000,000

1,000,000

'

'

200

200

200

'

'

'

600

600

600

Preferred Stock, Liquidation Preference, Value

'

'

'

'

'

'

$922,000

$5,000

'

'

$5,000

'

$887,500

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

5.00%

'

'

'

'

'

5.00%

'

'

Preferred Stock, Par or Stated Value Per Share

$0.00

$0.00

'

'

$5,000

'

'

'

'

'

$5,000

'

'

Preferred Stock, Dividend Payment Terms

'

'

'

'

'payable quarterly beginning on August 31, 2011

'

'

'

'

'

'payable quarterly beginning on December 31, 2011

'

'

Preferred Stock, Voting Rights

'

'

'

'

'no

'

'

'

'

'

'no

'

'

Preferred Stock, Redemption Terms

'

'

'

'

'The Series A preferred stock is mandatorily redeemable on December 31, 2014 (as modified) at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.

'

'

'

'

'

'The Series B preferred stock is mandatorily redeemable on December 31, 2014 at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.

'

'

Preferred Stock, Redemption Date

'

'

'

'

31-Dec-14

'

'

'

'

'

31-Dec-14

'

'

Preferred Stock Redemption, Percentage

'

'

'

'

14.00%

'

'

'

'

'

14.00%

'

'

Preferred Stock, Redemption Price Per Share

'

'

'

'

$1.84

'

'

'

'

'

$2.02

'

'

Preferred Stock, Shares Outstanding

'

184.4

'

'

'

'

184.4

'

'

'

'

'

177.5

Dividends Payable, Current

330,857

414,967

119,355

'

'

'

'

'

88,872

'

'

'

'

Conversion of Stock, Shares Issued

'

'

'

577,901

'

'

'

'

'

493,818

'

'

'

Conversion of Stock, Amount Converted

'

'

'

$141,331

'

'

'

'

'

$110,026

'

'

'

Preferred Stock, Shares Issued

'

'

'

'

'

184.4

184.4

'

'

'

'

177.5

177.5

NOTE_5_SERIES_C_9_CONVERTIBLE_1

NOTE 5 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

6 Months Ended

Jan. 31, 2014

Apr. 30, 2014

Jun. 30, 2014

Jan. 31, 2014

Dec. 31, 2013

Jan. 09, 2013

Jan. 09, 2013

Jan. 09, 2013

Jan. 09, 2013

Jan. 09, 2013

Jun. 30, 2014

Feb. 28, 2014

Jan. 31, 2014

Jun. 30, 2014

Dec. 31, 2013

Jan. 09, 2014

Jan. 09, 2013

Feb. 28, 2013

Mar. 31, 2014

Jun. 30, 2014

Jul. 31, 2013

Dec. 31, 2013

Jan. 09, 2013

Jan. 09, 2014

Jan. 09, 2014

Jan. 09, 2014

Jun. 30, 2014

Convertible Preferred Stock [Member]

Warrant [Member]

Issuance Costs [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Fair Value of Warrants [Member]

Fair Value of Warrants [Member]

Fair Value of Warrants [Member]

Securities Purchase Agreement [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Securities Purchase Agreement [Member]

Securities Purchase Agreement [Member]

Reset Previously Issued Warrants Exercise Price [Member]

Reset Previously Issued Warrants Exercise Price [Member]

Reset Previously Issued Warrants Exercise Price [Member]

Other Current Liabilities [Member]

Other Current Liabilities [Member]

Minimum [Member]

Maximum [Member]

NOTE 5 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized (in Shares)

'

'

1,000,000

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,200

'

4,200

4,200

'

'

'

'

Preferred Stock, Liquidation Preference, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,781,000

'

$2,781,000

$1,000

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

'

9.00%

9.00%

'

9.00%

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

'

'

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

Preferred Stock, Redemption Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.50

'

'

'

'

'

'

'

Preferred Stock, Redemption Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company's common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company's common stock, equal to a number of shares equal to the (i) above divided by 75%.

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Rights, Granted (in Shares)

64,626

137,856

'

'

'

'

'

'

1,330,627

'

984,674

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

$3.75

'

$3.67

'

'

'

'

'

$2.61

$1.50

$1.50

$2.61

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, Term of Warrants

'5 years

'5 years

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

Warrant, Description of Warrant

'

'

'

'

'

'

'

'

'after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no current prospectus available for the resale of the warrant shares by the holder, then the warrant may only be exercised, in whole or in part, at such time by means of a "cashless exercise" in which the holder shall be entitled to receive a number of Warrant Shares equal to defined formula.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Other

'

'

87,500

'

'

'

'

'

'

'

'

'

'

'

'

'

1,303,671

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Warrant Issued

'

'

52,800

'

'

'

'

'

'

'

'

'

'

'

'

'

1,064,739

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Discount on Shares

'

'

'

'

'

1,303,671

1,064,739

412,590

'

'

'

'

'

'

'

'

'

'

'

14,754

'

483,893

2,781,000

'

'

'

'

Debt Instrument, Convertible, Remaining Discount Amortization Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.39%

1.40%

'

Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

123.41%

125.33%

'

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,181

'

'

'

'

'

337,468

Proceeds from Issuance of Redeemable Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,814,910

'

'

'

'

'

'

Preferred Stock, Shares Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,781

2,781

'

2,781

'

'

'

'

'

Preferred Stock, Shares Outstanding (in Shares)

'

'

'

'

184.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,781

'

2,781

'

'

'

'

'

Dividends Payable, Current

'

'

330,857

'

414,967

'

'

'

'

'

'

'

'

330,856

206,740

'

'

'

'

'

'

'

'

'

'

'

'

Registration Payment Arrangement, Term

'

'

'The Company entered into a Registration Rights Agreement in connection with the sale and issuance of the Series C preferred stock. The Company is required to file a registration statement registering for resale the (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and "Make-Whole Payments" (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.The Company is required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company fails to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser's investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Registration Payment Arrangement, Accrual Carrying Value

'

'

$55,620

'

$48,668

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

NOTE_6_STOCKHOLDER_EQUITY_Deta

NOTE 6 - STOCKHOLDER EQUITY (Details) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Jan. 31, 2014

Apr. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 23, 2014

31-May-11

Jun. 30, 2014

Dec. 31, 2013

Jun. 23, 2014

Nov. 28, 2011

Jun. 30, 2014

Dec. 31, 2013

Jan. 09, 2013

Jan. 09, 2013

Mar. 31, 2014

Jun. 30, 2014

Jul. 31, 2013

Dec. 31, 2013

Jan. 09, 2013

Jun. 30, 2014

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Securities Purchase Agreement [Member]

Securities Purchase Agreement [Member]

NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

'

1,000,000

'

1,000,000

'

200

200

200

'

600

600

600

'

'

'

4,200

'

4,200

4,200

'

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

'

'

$0.00

'

$0.00

'

$5,000

'

'

'

$5,000

'

'

'

'

'

'

'

'

$1,000

'

Preferred Stock, Shares Issued

'

'

'

'

'

'

'

184.4

184.4

'

'

177.5

177.5

'

'

2,781

2,781

'

2,781

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

5.00%

'

'

'

5.00%

'

'

'

9.00%

9.00%

9.00%

'

9.00%

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities

'

'

'

'

'

577,901

'

'

'

493,818

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

'

50,000,000

'

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share (in Dollars per share)

'

'

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

'

'

9,821,288

'

8,412,101

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Outstanding

'

'

9,821,288

'

8,412,101

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,181

'

'

337,468

Warrants, Term of Warrants

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'5 years

Proceeds from Issuance of Common Stock (in Dollars)

'

'

$732,666

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$732,666

NOTE_7_OPTIONS_AND_WARRANTS_De

NOTE 7 - OPTIONS AND WARRANTS (Details) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

Jan. 31, 2014

Apr. 30, 2014

Jun. 30, 2014

Jan. 31, 2014

Jun. 30, 2014

Feb. 28, 2014

Jan. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Feb. 28, 2014

Jan. 31, 2014

Oct. 19, 2012

Oct. 19, 2012

Oct. 19, 2012

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Directors and Key Consultants [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Reset Previously Issued Warrants Exercise Price [Member]

Reset Previously Issued Warrants Exercise Price [Member]

2012 Equity Incentive Plan [Member]

2012 Equity Incentive Plan [Member]

2012 Equity Incentive Plan [Member]

Reset Previously Issued Warrants Exercise Price [Member]

Reset Previously Issued Warrants Exercise Price [Member]

Reset Previously Issued Warrants Exercise Price [Member]

Employee Stock Option [Member]

2012 Equity Incentive Plan [Member]

2012 Equity Incentive Plan [Member]

2012 Equity Incentive Plan [Member]

2012 Equity Incentive Plan [Member]

Maximum [Member]

2012 Equity Incentive Plan [Member]

NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

0

'

'

'

'

2,990,977

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value (in Dollars)

'

'

'

'

'

'

'

$3,380,851

'

'

'

'

'

'

'

'

'

'

Share Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$2.50

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)

'

'

'

'

'

'

'

'

212,495

643,555

556,332

2,658,870

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)

'

'

'

'

'

'

'

'

$544,106

'

$544,106

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

4,502,459

'

'

'

'

'

'

'

'

'

'

3,721,518

2,138,800

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

$3.75

'

$3.67

$1.50

$1.50

$2.61

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Rights, Granted

64,626

137,856

'

'

984,674

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, Term of Warrants

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

NOTE_7_OPTIONS_AND_WARRANTS_De1

NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]	'	'
Shares, Options Outstanding	'	2,990,977
Weighted-Average Exercise Price, Options Outstanding (in Dollars per share)	'	$2.05
Weighted-Average Remaining Contractual Term, Options Outstanding	'5 years 189 days	'6 years 7 days
Aggregate Intrinsic Value, Options Outstanding (in Dollars)	'	$0
Vested and expected to vest at June 30, 2014	2,990,977	'
Vested and expected to vest at June 30, 2014 (in Dollars per share)	$2.05	'
Vested and expected to vest at June 30, 2014	'5 years 189 days	'
Vested and expected to vest at June 30, 2014 (in Dollars)	1,343,204	'
Exercisable at June 30, 2014	1,904,659	'
Exercisable at June 30, 2014 (in Dollars per share)	$2.08	'
Exercisable at June 30, 2014	'5 years 270 days	'
Exercisable at June 30, 2014 (in Dollars)	805,734	'
Grants	0	'
Exercised	0	'
Forfeitures or expirations	0	'
Shares, Options Outstanding	2,990,977	'
Weighted-Average Exercise Price, Options Outstanding (in Dollars per share)	$2.05	'
Aggregate Intrinsic Value, Options Outstanding (in Dollars)	$1,343,204	'

NOTE_7_OPTIONS_AND_WARRANTS_De2

NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range (USD $)

Jun. 30, 2014

Apr. 30, 2014

Jan. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Warrants at $0.001 [Member]

Warrants at $0.001 [Member]

Warrants at $1.50 [Member]

Warrants at $1.50 [Member]

Warrants at $1.50 [Member]

Warrants at $1.84 [Member]

Warrants at $1.84 [Member]

Warrants at $2.02 [Member]

Warrants at $2.02 [Member]

Warrants at $3.67 [Member]

Warrants at $3.67 [Member]

Warrants at $3.67 [Member]

Warrants at $3.75 [Member]

Warrants at $3.75 [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price, Warrants

'

$3.75

$3.67

$0.00

'

$1.50

'

'

$1.84

'

$2.02

'

$3.67

'

'

$3.75

'

Number of Warrants Outstanding

4,502,459

'

'

383,320

'

3,721,518

'

'

35,076

'

30,755

'

193,934

'

'

137,856

'

Experation Date, Warrants

'

'

'

'

'January 2020

'

'February 2018

'September 2018

'

'January 2020

'

'January 2020

'

'December 2018

'January 2019

'

'April 2019

NOTE_8_RELATED_PARTY_TRANSACTI1

NOTE 8 - RELATED PARTY TRANSACTIONS (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]	'	'
Due to Related Parties, Current	$500	$30,781
Adjustments to Additional Paid in Capital, Other	87,500	'
Director [Member]	'	'
NOTE 8 - RELATED PARTY TRANSACTIONS (Details) [Line Items]	'	'
Adjustments to Additional Paid in Capital, Other	$87,500	'

NOTE_9_COMMITMENTS_AND_CONTING1

NOTE 9 - COMMITMENTS AND CONTINGENCIES (Details) (USD $)	0 Months Ended
	31-May-14	Jan. 07, 2014
NOTE 9 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]	'	'
Lessee Leasing Arrangements, Operating Leases, Term of Contract	'3 years	'
Lessee Leasing Arrangements, Operating Leases, Renewal Term	'1 year	'
Operating Leases, Rent Expense, Minimum Rentals	$6,530	'
Loss Contingency, Damages Sought	'	'(a) payment of his salary and pro-rated bonus for the time he served in his positions with the Company and the severance payments due under his employment agreement, which include 12 months of base salary and full bonus payments, with the total sum of payments equaling approximately $612,000, including $58,000 of accrued and unpaid salary, (b) full vesting of stock options equivalent to 10% of our outstanding common stock, and (c) a declaration by us that Mr. Drachman has full rights to the ownership and control of the patent application related to a combined ablation and recording unit that the Company filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with the Company.
Severance Agreement [Member]	'	'
NOTE 9 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]	'	'
Loss Contingency, Damages Sought, Value	'	612,000
Accrued and Unpaid Salary [Member]	'	'
NOTE 9 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]	'	'
Loss Contingency, Damages Sought, Value	'	58,000

NOTE_10_FAIR_VALUE_OF_FINANCIA1

NOTE 10 - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
Fair Value, Net Asset (Liability)	$0	$0

NOTE_11_SUBSEQUENT_EVENTS_Deta

NOTE 11 - SUBSEQUENT EVENTS (Details) (USD $)

6 Months Ended

0 Months Ended

Jun. 30, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Jul. 14, 2014

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Securities Purchase Agreement [Member]

Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Award, Tranche Three [Member]

Share-based Compensation Award, Tranche Four [Member]

Share-based Compensation Award, Tranche Five [Member]

Maximum [Member]

Private Placement Agent [Member]

Options Vesting in Eleven Equal Installments [Member]

Final Installment of Vested Options [Member]

NOTE 11 - SUBSEQUENT EVENTS (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of Directors

'

'

'

'

'

'

'

'

'

'

8

'

Other Commitments, Description

'

'

'

'

'

'

'

'

'

'The Employment Agreement has an initial term of three years that expires on July 15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a "Qualified Financing"), Mr. Cash's annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash's annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.

'

'

Other Commitment (in Dollars)

'

'

'

'

'

'

'

'

'

'

$275,000

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

0

'

'

'

'

'

'

'

'

1,265,769

'

'

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

$2.21

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'10 years

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

'

'

45,206

45,207

542,473

180,824

180,824

180,824

180,824

'

'

'

Number of Installments for Vested Options

'

'

11

1

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'3 months

'

'

'

'

'

'

'

Capital (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

$150,000,000